Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer

doi:10.4251/wjgo.v12.i6.687

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7356)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

263

WORD

145

HTML

3986

Figures (1-5)

237

Tables (1-2)

264

Sum=4895

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

967

Download

1494

Sum=2461

Jun 15, 2020 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Oncol. Jun 15, 2020; 12(6): 687-698
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.687

Table 2 Meta-analysis and subgroup analyses

Analysis	n	Ref.	Random-effects model		Fixed-effects model		Heterogeneity
Analysis	n	Ref.	HR (95%CI)	P value	HR (95%CI)	P value	I²	Ph
Esophageal cancer OS	16	[5,7-11,13,16-24]	1.107 (1.014-1.208)	0.023	1.089 (1.036-1.145)	0.001^a	48.80%	0.015
DFS	3	[17,21,23]	1.300 (0.883-1.913)	0.184	1.263 (0.976-1.633)	0.075	48.40%	0.144
Subgroup 1: Study design	16	[5,7-11,13,16-24]	1.107 (1.014-1.208)	0.196	1.089 (1.036-1.145)	0.196	0.00	0.865
Prospective	9	[5,8,16-18,20-22,24]	1.073 (0.964-1.194)	0.064	1.073 (0.964-1.194)	0.002^a	76.30%	0.000
Retrospective	7	[7,9-11,13,19,23]	1.150 (0.992-1.332)	0.023^a	1.094 (1.034-1.158)	0.001^a	48.80%	0.015
Subgroup 2: Samplesize	16	[5,7-11,13,16-24]	1.107 (1.014-1.208)	0.023^a	1.089 (1.036-1.145)	0.001^a	48.80%	0.015
< 200	5	[16,19,21-23]	1.294 (0.946-1.771)	0.107	1.254 (0.985-1.597)	0.067	34.70%	0.190
≥ 200	11	[5,7-11,13,17,18,20,24]	1.089 (0.995-1.190)	0.063	1.082 (1.028-1.139)	0.002^a	54.20%	0.016
Subgroup 3: Ethnicity	16	[5,7-11,13,16-24]	1.107 (1.014-1.208)	0.064	1.107 (1.014-1.208)	0.064	48.80%	0.015
Caucasian	12	[5,7-9,11,13,16-19,21,24]	1.091 (0.995-1.197)	0.150	1.091 (0.995-1.197)	0.150	49.30%	0.027
Asian	4	[10,20,22,23]	1.251 (0.922-1.696)	0.023^a	1.251 (0.922-1.696)	0.023^a	57.60%	0.069
Subgroup 4: HR type	16	[5,7-11,13,16-24]	1.107 (1.014-1.208)	0.023^a	1.089 (1.036-1.145)	0.001^a	48.80%	0.015
Univariate	13	[5,8,10,13,16-24]	1.053 (0.952-1.166)	0.314	1.029 (0.949-1.115)	0.492	23.20%	0.209
Multivariate	3	[7,9,11]	1.194 (1.010-1.411)	0.037^a	1.130 (1.059-1.204)	0.000^a	81.00%	0.005
Squamous cell carcinoma OS	6	[10,13,16,20,22,23]	1.096 (0.896-1.341)	0.371	1.009 (0.908-1.120)	0.874	57.20%	0.039
Adenocarcinoma OS	2	[9,21]	1.360 (1.111-1.664)	0.003^a	1.385 (1.186-1.616)	0.000^a	22.00%	0.257

^aStatistical significance. n: Number of studies; HR: Hazard ratio; 95%CI: 95% confidence interval; Ph: P values of Q test for heterogeneity test; OS: Overall survival; DFS: Disease free survival.

Citation: Shang QX, Yang YS, Gu YM, Zeng XX, Zhang HL, Hu WP, Wang WP, Chen LQ, Yuan Y. Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer. World J Gastrointest Oncol 2020; 12(6): 687-698
URL: https://www.wjgnet.com/1948-5204/full/v12/i6/687.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.687